Research programme: anti-fibrotic therapeutics - Connexios

Drug Profile

Research programme: anti-fibrotic therapeutics - Connexios

Alternative Names: CNX-014; CNX-023; CNX-024; CNX-025

Latest Information Update: 02 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Connexios Life Sciences
  • Class
  • Mechanism of Action G protein-coupled receptor modulators; Mitogen-activated protein kinase modulators; Peptide hydrolase modulators; Protein kinase modulators; Protein tyrosine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Fibrosis

Most Recent Events

  • 15 Oct 2015 Early research in Fibrosis in India before October 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top